Stay updated on Nivolumab Combo in Relapsed/Refractory HL Clinical Trial

Sign up to get notified when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-05-01T06:04:34.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The webpage has been updated to include new information about the clinical trial for recurrent Hodgkin Lymphoma, specifically mentioning the use of Nivolumab and the involvement of the National Cancer Institute. Additionally, the revision number has been updated to v2.15.0.
    Difference
    50%
    Check dated 2025-04-16T17:23:24.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.0%
    Check dated 2025-04-09T11:42:12.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.0%
    Check dated 2025-04-01T23:55:22.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.8%
    Check dated 2025-02-24T22:43:50.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.8%
    Check dated 2025-02-10T15:30:36.000Z thumbnail image

Stay in the know with updates to Nivolumab Combo in Relapsed/Refractory HL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.